2013 -- S 0428 SUBSTITUTE A

=======

LC01278/SUB A

=======

STATE OF RHODE ISLAND

IN GENERAL ASSEMBLY

JANUARY SESSION, A.D. 2013

____________

A N A C T

RELATING TO INSURANCE - ORALLY ADMINISTERED ANTICANCER MEDICATION

     Introduced By: Senators Goldin, Ottiano, Jabour, Picard, and Cool Rumsey

     Date Introduced: February 26, 2013

     Referred To: Senate Health & Human Services

It is enacted by the General Assembly as follows:

1-1

     SECTION 1. Chapter 27-18 of the General Laws entitled "Accident and Sickness

1-2

Insurance Policies" is hereby amended by adding thereto the following section:

1-3

     27-18-80. Orally administered anticancer medication - Cost-sharing requirement. –

1-4

(a) Every individual or group hospital or medical expense, insurance policy or individual or group

1-5

hospital or medical services plan contract, plan or certificate of insurance delivered, issued for

1-6

delivery, or renewed in this state, on or after January 1, 2014, that offers both medical and

1-7

prescription drug coverage, and provides coverage for intravenously administered anticancer

1-8

medication, shall provide coverage for prescribed, orally administered anticancer medications

1-9

used to kill or slow the growth of cancerous cells on a basis no less favorable than intravenously

1-10

administered or injected cancer medications that are covered as medical benefits. An increase in

1-11

patient cost sharing for anticancer medications shall not be allowed to achieve compliance with

1-12

this section. Notwithstanding the above, the requirements shall not be construed to impose any

1-13

form of cap on cost-sharing.

1-14

     (b) This section does not apply to insurance coverage providing benefits for: (1) Hospital

1-15

confinement indemnity; (2) Disability income; (3) Accident only; (4) Long-term care; (5)

1-16

Medicare supplement; (6) Limited benefit health; (7) Specified disease indemnity; (8) Sickness or

1-17

bodily injury or death by accident or both; and (9) Other limited benefit policies.

1-18

     SECTION 2. Chapter 27-19 of the General Laws entitled "Nonprofit Hospital Service

1-19

Corporations" is hereby amended by adding thereto the following section:

2-20

     27-19-71. Orally administered anticancer medication – Cost-sharing requirement. –

2-21

(a) Every individual or group hospital or medical expense, insurance policy or individual or group

2-22

hospital or medical services plan contract, plan or certificate of insurance delivered, issued for

2-23

delivery, or renewed in this state, on or after January 1, 2014, that offers both medical and

2-24

prescription drug coverage, and provides coverage for intravenously administered anticancer

2-25

medication, shall provide coverage for prescribed, orally administered anticancer medications

2-26

used to kill or slow the growth of cancerous cells on a basis no less favorable than intravenously

2-27

administered or injected cancer medications that are covered as medical benefits. An increase in

2-28

patient cost sharing for anticancer medications shall not be allowed to achieve compliance with

2-29

this section. Notwithstanding the above, the requirements shall not be construed to impose any

2-30

form of cap on cost-sharing.

2-31

     (b) This section does not apply to insurance coverage providing benefits for: (1) Hospital

2-32

confinement indemnity; (2) Disability income; (3) Accident only; (4) Long-term care; (5)

2-33

Medicare supplement; (6) Limited benefit health; (7) Specified disease indemnity; (8) Sickness or

2-34

bodily injury or death by accident or both; and (9) Other limited benefit policies.

2-35

     SECTION 3. Chapter 27-20 of the General Laws entitled "Nonprofit Medical Service

2-36

Corporations" is hereby amended by adding thereto the following section:

2-37

     27-20-67. Orally administered anticancer medication – Cost-sharing requirement. –

2-38

(a) Every individual or group hospital or medical expense, insurance policy or individual or group

2-39

hospital or medical services plan contract, plan or certificate of insurance delivered, issued for

2-40

delivery, or renewed in this state, on or after January 1, 2014, that offers both medical and

2-41

prescription drug coverage, and provides coverage for intravenously administered anticancer

2-42

medication, shall provide coverage for prescribed, orally administered anticancer medications

2-43

used to kill or slow the growth of cancerous cells on a basis no less favorable than intravenously

2-44

administered or injected cancer medications that are covered as medical benefits. An increase in

2-45

patient cost sharing for anticancer medications shall not be allowed to achieve compliance with

2-46

this section. Notwithstanding the above, the requirements shall not be construed to impose any

2-47

form of cap on cost-sharing.

2-48

     (b) This section does not apply to insurance coverage providing benefits for: (1) Hospital

2-49

confinement indemnity; (2) Disability income; (3) Accident only; (4) Long-term care; (5)

2-50

Medicare supplement; (6) Limited benefit health; (7) Specified disease indemnity; (8) Sickness or

2-51

bodily injury or death by accident or both; and (9) Other limited benefit policies.

2-52

     SECTION 4. Chapter 27-41 of the General Laws entitled "Health Maintenance

2-53

Organizations" is hereby amended by adding thereto the following section:

3-54

      27-41-84. Orally administered anticancer medication – Cost-sharing requirement. –

3-55

(a) Every individual or group hospital or medical expense, insurance policy or individual or group

3-56

hospital or medical services plan contract, plan or certificate of insurance delivered, issued for

3-57

delivery, or renewed in this state, on or after January 1, 2014 ,that offers both medical and

3-58

prescription drug coverage, and provides coverage for intravenously administered anticancer

3-59

medication, shall provide coverage for prescribed, orally administered anticancer medications

3-60

used to kill or slow the growth of cancerous cells on a basis no less favorable than intravenously

3-61

administered or injected cancer medications that are covered as medical benefits. An increase in

3-62

patient cost sharing for anticancer medications shall not be allowed to achieve compliance with

3-63

this section. Notwithstanding the above, the requirements shall not be construed to impose any

3-64

form of cap on cost-sharing.

3-65

     (b) This section does not apply to insurance coverage providing benefits for: (1) Hospital

3-66

confinement indemnity; (2) Disability income; (3) Accident only; (4) Long-term care; (5)

3-67

Medicare supplement; (6) Limited benefit health; (7) Specified disease indemnity; (8) Sickness or

3-68

bodily injury or death by accident or both; and (9) Other limited benefit policies.

3-69

     SECTION 5. Section 42-14.5-3 of the General Laws in Chapter 42-14.5 entitled "The

3-70

Rhode Island Health Care Reform Act of 2004 - Health Insurance Oversight" is hereby amended

3-71

to read as follows:

3-72

     42-14.5-3. Powers and duties. [Contingent effective date; see effective dates under

3-73

this section.] -- The health insurance commissioner shall have the following powers and duties:

3-74

     (a) To conduct quarterly public meetings throughout the state, separate and distinct from

3-75

rate hearings pursuant to section 42-62-13, regarding the rates, services and operations of insurers

3-76

licensed to provide health insurance in the state the effects of such rates, services and operations

3-77

on consumers, medical care providers, patients, and the market environment in which such

3-78

insurers operate and efforts to bring new health insurers into the Rhode Island market. Notice of

3-79

not less than ten (10) days of said hearing(s) shall go to the general assembly, the governor, the

3-80

Rhode Island Medical Society, the Hospital Association of Rhode Island, the director of health,

3-81

the attorney general and the chambers of commerce. Public notice shall be posted on the

3-82

department's web site and given in the newspaper of general circulation, and to any entity in

3-83

writing requesting notice.

3-84

     (b) To make recommendations to the governor and the house of representatives and

3-85

senate finance committees regarding health care insurance and the regulations, rates, services,

3-86

administrative expenses, reserve requirements, and operations of insurers providing health

3-87

insurance in the state, and to prepare or comment on, upon the request of the governor, or

3-88

chairpersons of the house or senate finance committees, draft legislation to improve the regulation

4-1

of health insurance. In making such recommendations, the commissioner shall recognize that it is

4-2

the intent of the legislature that the maximum disclosure be provided regarding the

4-3

reasonableness of individual administrative expenditures as well as total administrative costs. The

4-4

commissioner shall also make recommendations on the levels of reserves including consideration

4-5

of: targeted reserve levels; trends in the increase or decrease of reserve levels; and insurer plans

4-6

for distributing excess reserves.

4-7

      (c) To establish a consumer/business/labor/medical advisory council to obtain

4-8

information and present concerns of consumers, business and medical providers affected by

4-9

health insurance decisions. The council shall develop proposals to allow the market for small

4-10

business health insurance to be affordable and fairer. The council shall be involved in the

4-11

planning and conduct of the quarterly public meetings in accordance with subsection (a) above.

4-12

The advisory council shall develop measures to inform small businesses of an insurance

4-13

complaint process to ensure that small businesses that experience rate increases in a given year

4-14

may request and receive a formal review by the department. The advisory council shall assess

4-15

views of the health provider community relative to insurance rates of reimbursement, billing and

4-16

reimbursement procedures, and the insurers' role in promoting efficient and high quality health

4-17

care. The advisory council shall issue an annual report of findings and recommendations to the

4-18

governor and the general assembly and present their findings at hearings before the house and

4-19

senate finance committees. The advisory council is to be diverse in interests and shall include

4-20

representatives of community consumer organizations; small businesses, other than those

4-21

involved in the sale of insurance products; and hospital, medical, and other health provider

4-22

organizations. Such representatives shall be nominated by their respective organizations. The

4-23

advisory council shall be co-chaired by the health insurance commissioner and a community

4-24

consumer organization or small business member to be elected by the full advisory council.

4-25

      (d) To establish and provide guidance and assistance to a subcommittee ("The

4-26

Professional Provider-Health Plan Work Group") of the advisory council created pursuant to

4-27

subsection (c) above, composed of health care providers and Rhode Island licensed health plans.

4-28

This subcommittee shall include in its annual report and presentation before the house and senate

4-29

finance committees the following information:

4-30

      (i) A method whereby health plans shall disclose to contracted providers the fee

4-31

schedules used to provide payment to those providers for services rendered to covered patients;

4-32

      (ii) A standardized provider application and credentials verification process, for the

4-33

purpose of verifying professional qualifications of participating health care providers;

5-34

      (iii) The uniform health plan claim form utilized by participating providers;

5-35

      (iv) Methods for health maintenance organizations as defined by section 27-41-1, and

5-36

nonprofit hospital or medical service corporations as defined by chapters 27-19 and 27-20, to

5-37

make facility-specific data and other medical service-specific data available in reasonably

5-38

consistent formats to patients regarding quality and costs. This information would help consumers

5-39

make informed choices regarding the facilities and/or clinicians or physician practices at which to

5-40

seek care. Among the items considered would be the unique health services and other public

5-41

goods provided by facilities and/or clinicians or physician practices in establishing the most

5-42

appropriate cost comparisons.

5-43

      (v) All activities related to contractual disclosure to participating providers of the

5-44

mechanisms for resolving health plan/provider disputes; and

5-45

      (vi) The uniform process being utilized for confirming in real time patient insurance

5-46

enrollment status, benefits coverage, including co-pays and deductibles.

5-47

      (vii) Information related to temporary credentialing of providers seeking to participate in

5-48

the plan's network and the impact of said activity on health plan accreditation;

5-49

      (viii) The feasibility of regular contract renegotiations between plans and the providers

5-50

in their networks.

5-51

      (ix) Efforts conducted related to reviewing impact of silent PPOs on physician practices.

5-52

      (e) To enforce the provisions of Title 27 and Title 42 as set forth in section 42-14-5(d).

5-53

      (f) To provide analysis of the Rhode Island Affordable Health Plan Reinsurance Fund.

5-54

The fund shall be used to effectuate the provisions of sections 27-18.5-8 and 27-50-17.

5-55

      (g) To analyze the impact of changing the rating guidelines and/or merging the

5-56

individual health insurance market as defined in chapter 27-18.5 and the small employer health

5-57

insurance market as defined in chapter 27-50 in accordance with the following:

5-58

      (i) The analysis shall forecast the likely rate increases required to effect the changes

5-59

recommended pursuant to the preceding subsection (g) in the direct pay market and small

5-60

employer health insurance market over the next five (5) years, based on the current rating

5-61

structure, and current products.

5-62

      (ii) The analysis shall include examining the impact of merging the individual and small

5-63

employer markets on premiums charged to individuals and small employer groups.

5-64

      (iii) The analysis shall include examining the impact on rates in each of the individual

5-65

and small employer health insurance markets and the number of insureds in the context of

5-66

possible changes to the rating guidelines used for small employer groups, including: community

5-67

rating principles; expanding small employer rate bonds beyond the current range; increasing the

5-68

employer group size in the small group market; and/or adding rating factors for broker and/or

6-1

tobacco use.

6-2

      (iv) The analysis shall include examining the adequacy of current statutory and

6-3

regulatory oversight of the rating process and factors employed by the participants in the

6-4

proposed new merged market.

6-5

      (v) The analysis shall include assessment of possible reinsurance mechanisms and/or

6-6

federal high-risk pool structures and funding to support the health insurance market in Rhode

6-7

Island by reducing the risk of adverse selection and the incremental insurance premiums charged

6-8

for this risk, and/or by making health insurance affordable for a selected at-risk population.

6-9

      (vi) The health insurance commissioner shall work with an insurance market merger task

6-10

force to assist with the analysis. The task force shall be chaired by the health insurance

6-11

commissioner and shall include, but not be limited to, representatives of the general assembly, the

6-12

business community, small employer carriers as defined in section 27-50-3, carriers offering

6-13

coverage in the individual market in Rhode Island, health insurance brokers and members of the

6-14

general public.

6-15

      (vii) For the purposes of conducting this analysis, the commissioner may contract with

6-16

an outside organization with expertise in fiscal analysis of the private insurance market. In

6-17

conducting its study, the organization shall, to the extent possible, obtain and use actual health

6-18

plan data. Said data shall be subject to state and federal laws and regulations governing

6-19

confidentiality of health care and proprietary information.

6-20

      (viii) The task force shall meet as necessary and include their findings in the annual

6-21

report and the commissioner shall include the information in the annual presentation before the

6-22

house and senate finance committees.

6-23

      (h) To establish and convene a workgroup representing health care providers and health

6-24

insurers for the purpose of coordinating the development of processes, guidelines, and standards

6-25

to streamline health care administration that are to be adopted by payors and providers of health

6-26

care services operating in the state. This workgroup shall include representatives with expertise

6-27

that would contribute to the streamlining of health care administration and that are selected from

6-28

hospitals, physician practices, community behavioral health organizations, each health insurer

6-29

and other affected entities. The workgroup shall also include at least one designee each from the

6-30

Rhode Island Medical Society, Rhode Island Council of Community Mental Health

6-31

Organizations, the Rhode Island Health Center Association, and the Hospital Association of

6-32

Rhode Island. The workgroup shall consider and make recommendations for:

6-33

      (1) Establishing a consistent standard for electronic eligibility and coverage verification.

6-34

Such standard shall:

7-1

      (i) Include standards for eligibility inquiry and response and, wherever possible, be

7-2

consistent with the standards adopted by nationally recognized organizations, such as the centers

7-3

for Medicare and Medicaid services;

7-4

      (ii) Enable providers and payors to exchange eligibility requests and responses on a

7-5

system-to-system basis or using a payor supported web browser;

7-6

      (iii) Provide reasonably detailed information on a consumer's eligibility for health care

7-7

coverage, scope of benefits, limitations and exclusions provided under that coverage, cost-sharing

7-8

requirements for specific services at the specific time of the inquiry, current deductible amounts,

7-9

accumulated or limited benefits, out-of-pocket maximums, any maximum policy amounts, and

7-10

other information required for the provider to collect the patient's portion of the bill;

7-11

      (iv) Reflect the necessary limitations imposed on payors by the originator of the

7-12

eligibility and benefits information;

7-13

      (v) Recommend a standard or common process to protect all providers from the costs of

7-14

services to patients who are ineligible for insurance coverage in circumstances where a payor

7-15

provides eligibility verification based on best information available to the payor at the date of the

7-16

request of eligibility.

7-17

      (2) Developing implementation guidelines and promoting adoption of such guidelines

7-18

for:

7-19

      (i) The use of the national correct coding initiative code edit policy by payors and

7-20

providers in the state;

7-21

      (ii) Publishing any variations from codes and mutually exclusive codes by payors in a

7-22

manner that makes for simple retrieval and implementation by providers;

7-23

      (iii) Use of health insurance portability and accountability act standard group codes,

7-24

reason codes, and remark codes by payors in electronic remittances sent to providers;

7-25

      (iv) The processing of corrections to claims by providers and payors.

7-26

      (v) A standard payor denial review process for providers when they request a

7-27

reconsideration of a denial of a claim that results from differences in clinical edits where no

7-28

single, common standards body or process exists and multiple conflicting sources are in use by

7-29

payors and providers.

7-30

      (vi) Nothing in this section or in the guidelines developed shall inhibit an individual

7-31

payor's ability to employ, and not disclose to providers, temporary code edits for the purpose of

7-32

detecting and deterring fraudulent billing activities. The guidelines shall require that each payor

7-33

disclose to the provider its adjudication decision on a claim that was denied or adjusted based on

7-34

the application of such edits and that the provider have access to the payor's review and appeal

8-1

process to challenge the payor's adjudication decision.

8-2

      (vii) Nothing in this subsection shall be construed to modify the rights or obligations of

8-3

payors or providers with respect to procedures relating to the investigation, reporting, appeal, or

8-4

prosecution under applicable law of potentially fraudulent billing activities.

8-5

      (3) Developing and promoting widespread adoption by payors and providers of

8-6

guidelines to:

8-7

      (i) Ensure payors do not automatically deny claims for services when extenuating

8-8

circumstances make it impossible for the provider to obtain a preauthorization before services are

8-9

performed or notify a payor within an appropriate standardized timeline of a patient's admission;

8-10

      (ii) Require payors to use common and consistent processes and time frames when

8-11

responding to provider requests for medical management approvals. Whenever possible, such

8-12

time frames shall be consistent with those established by leading national organizations and be

8-13

based upon the acuity of the patient's need for care or treatment. For the purposes of this section,

8-14

medical management includes prior authorization of services, preauthorization of services,

8-15

precertification of services, post service review, medical necessity review, and benefits advisory;

8-16

      (iii) Develop, maintain, and promote widespread adoption of a single common website

8-17

where providers can obtain payors' preauthorization, benefits advisory, and preadmission

8-18

requirements;

8-19

      (iv) Establish guidelines for payors to develop and maintain a website that providers can

8-20

use to request a preauthorization, including a prospective clinical necessity review; receive an

8-21

authorization number; and transmit an admission notification.

8-22

     (i) To issue an ANTI-CANCER MEDICATION REPORT. Not later than June 30, 2014

8-23

and annually thereafter, the office of the health insurance commissioner (OHIC) shall provide the

8-24

senate committee on health and human services, and the house committee on corporations, with:

8-25

(1) Information on the availability in the commercial market of coverage for anti-cancer

8-26

medication options; (2) For the state employee's health benefit plan, the costs of various cancer

8-27

treatment options; (3) The changes in drug prices over the prior thirty-six (36) months; and (4)

8-28

Member utilization and cost-sharing expense.

8-29

     SECTION 6. This act shall take effect upon passage.

=======

LC01278/SUB A

========

EXPLANATION

BY THE LEGISLATIVE COUNCIL

OF

A N A C T

RELATING TO INSURANCE - ORALLY ADMINISTERED ANTICANCER MEDICATION

***

9-1

     This act would require insurance coverage for prescribed, orally administered anticancer

9-2

medication where there is coverage for intravenously administered or injected anticancer

9-3

medications.

9-4

     This act would take effect upon passage.

=======

LC01278/SUB A

=======